openPR Logo
Press release

Antisense & RNAi Therapeutics Market 2021 : Trends, Business Growth And Major Driving Factors

12-08-2021 06:18 AM CET | Health & Medicine

Press release from: The Business research company

Antisense & RNAi Therapeutics Market

Antisense & RNAi Therapeutics Market

Get up to 33% off on ALL market research reports at The Business Research Company's holiday sale; buy now!
https://www.thebusinessresearchcompany.com/global-market-reports

‘Antisense & RNAi Therapeutics Global Market Report 2021 – COVID-19 Growth And Change’ by The Business Research Company is the most comprehensive report available on this market, with analysis of the market’s historic and forecast growth, drivers and restraints causing this, and highlights of the opportunities that companies in the industry can take on. The market research report helps gain a truly global perspective of the antisense & rnai therapeutics industry as it covers 60 geographies. Regional and country breakdowns give an analysis of the market in each geography, with information on the size of the market by region and by country.

The countries covered in the global antisense & rnai therapeutics market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam.

The regions covered in the global antisense & rnai therapeutics market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Know What You Need? Directly Purchase The Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389

The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.

The global antisense & rnai therapeutics market is expected to grow from $1.11 billion in 2020 to $1.2 billion in 2021 at a compound annual growth rate (CAGR) of 8.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.79 billion in 2025 at a CAGR of 11%.

Request For A Sample Of The Antisense & RNAi Therapeutics Market Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

The global antisense & RNAi therapeutics market is segmented -
1) By Technology: RNA Interference, Antisense RNA
2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other

The major players covered in the global antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics, Antisense Therapeutics Ltd., Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals), Bio-Path Holdings Inc., Calando Pharmaceuticals, Dicerna Pharmaceuticals, Enzon Pharmaceuticals Inc, Gradalis, iCo Therapeutics, miRagen Therapeutics, Olix Pharmaceuticals, OncoGeneX Pharmaceuticals, Lorus Therapeutics (Aptose Biosciences), Regulus Therapeutics, Rexahn Pharmaceuticals, Rxi Pharmaceuticals, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Silence Therapeutics Plc, Sirnaomics Inc., Tekmira Pharmaceuticals, Cenix BioScience, Sirnaomics.

Need More? Read Further On The Antisense & RNAi Therapeutics Market Here:
https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-market-global-report-2020-30-covid-19-growth-and-change

The Table of Contents includes:
1. Executive Summary
2. Antisense & RNAi Therapeutics Market Characteristics
3. Antisense & RNAi Therapeutics Market Trends And Strategies
4. Impact Of COVID-19 On Antisense & RNAi Therapeutics
5. Antisense & RNAi Therapeutics Market Size And Growth
.....
28. Antisense & RNAi Therapeutics Pipeline Analysis
29. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market
30. Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis
31. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Interested to know more about The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. Located globally, it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Get a glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

The World’s Most Comprehensive Database
The Business Research Company’s flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antisense & RNAi Therapeutics Market 2021 : Trends, Business Growth And Major Driving Factors here

News-ID: 2488984 • Views:

More Releases from The Business research company

Automated Machine Learning (AutoML) Market 2024-2033: Size, Share & Competitive Landscape Analysis
Automated Machine Learning (AutoML) Market 2024-2033: Size, Share & Competitive …
The automated machine learning (automl) market size has grown exponentially in recent years. It will grow from $1.15 billion in 2023 to $1.67 billion in 2024 at a compound annual growth rate (CAGR) of 44.9%. The growth in the historic period can be attributed to complexity of machine learning, scarcity of data science talent, demand for speedy solutions, advancements in ai and computing power, cost efficiency. The automated machine
Menopausal Hot Flashes Market 2024-2033: Growth Trends, Forecast & Competitive Landscape
Menopausal Hot Flashes Market 2024-2033: Growth Trends, Forecast & Competitive L …
The menopausal hot flashes market size has grown strongly in recent years. It will grow from $14.06 billion in 2023 to $14.99 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to hormone replacement therapy, limited treatment options, awareness and education, shift in lifestyle management, alternative therapies:. The menopausal hot flashes market size is expected to see
Water Quality Testing Equipment Market 2024-2033: Trends, Analysis & Growth Forecast
Water Quality Testing Equipment Market 2024-2033: Trends, Analysis & Growth Fore …
The water quality testing equipment market size has grown strongly in recent years. It will grow from $4.32 billion in 2023 to $4.64 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to regulatory compliance, industrialization impact, public health concerns, environmental awareness. The water quality testing equipment market size is expected to see strong growth in the
Robotic Endoscopy Devices Market 2024-2033: Size, Share & Competitive Landscape Analysis
Robotic Endoscopy Devices Market 2024-2033: Size, Share & Competitive Landscape …
The robotic endoscopy devices market size has grown rapidly in recent years. It will grow from $2.14 billion in 2023 to $2.53 billion in 2024 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to aging population, increasing demand for minimally invasive procedures, rising awareness of early disease detection, regulatory approvals, growing prevalence of gastrointestinal disorders. The robotic endoscopy devices

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and